IP Library Granted Patent US 11,141,549
Granted Patent B2
US 11,141,549 · App. 15/010,999 · Granted Oct 12, 2021

Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide

Inventors: Craig R. Tolmie (Stoughton, WI); Jeff Milsap (Cambridge, WI); Jaron M. Acker (Madison, WI)
Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
A61M16/0051A61M16/0003A61M16/024A61M16/085A61M16/1005A61M16/12A61M16/201G01N27/4163G01N33/0006G01N33/0008G01N33/0037A61M16/16A61M2016/102A61M2016/1035A61M2202/0275A61M2205/18A61M2205/27A61M2205/33A61M2205/502A61M2205/52A61M2205/581A61M2205/583A61M2205/70A61M2205/702Y02A50/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,141,549
App. No.
15/010,999
Filed
Jan 29, 2016
Granted
Oct 12, 2021
Kind
B2
Art Unit
3785
USPC
128/202.22
Abstract

Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient. In at least some instances, the long term sensitivity drift of catalytic type electrochemical gas sensors can be addressed using calibration schedules, which can factor in the absolute change in set dose of NO being delivered to the patient that can drive one or more baseline calibrations. The calibration schedules can be used reduce the amount of times the sensor goes offline. Systems and methods described may factor in in actions occurring at the delivery system and/or aspects of the surrounding environment, prior to performing a baseline calibration, and may postpone the calibration and/or rejected using the sensor's output for the calibration.

Claims (49)

1. A gas delivery system, comprising:

a gas delivery subsystem configured to deliver therapeutic gas comprising nitric oxide from a therapeutic gas source to a breathing circuit of a patient;

a system controller including a processor in communication with a memory;

the memory having stored thereon a calibration schedule for performing a plurality of baseline calibrations and a calibration line correlating of expected sensor output values from at least one sensor to therapeutic gas concentration;

at least one sensor configured to measure a concentration of the therapeutic gas;

wherein the system controller is configured to adjust the measurements of the at least one sensor according to the correlation of sensor outputs to therapeutic gas concentration;

wherein the system controller is configured to cause the at least one sensor to be calibrated according to the calibration schedule that dictates when the plurality of baseline calibrations should occur, wherein the calibration schedule is changed upon a change in a set dosage, wherein the calibration schedule is based on the set dosage;

wherein during the plurality of baseline calibrations the at least one sensor measures an actual output value indicative of a zero concentration of the therapeutic gas while only being exposed to a gas having a zero concentration of the therapeutic gas; and

wherein the system controller is configured to adjust the correlation of expected sensor output values to therapeutic gas concentration according to the difference in the actual output value and the expected output value.

2. The gas delivery system of claim 1 , wherein the system controller is configured to postpone a scheduled calibration of the at least one sensor when there is an alarm condition.

3. The gas delivery system of claim 1 , wherein the system controller is configured to postpone a scheduled calibration of the at least one sensor when an alarm condition occurs within a predetermined interval before the scheduled calibration.

4. The gas delivery system of claim 1 , further comprising:

the breathing circuit configured for delivery of the therapeutic gas to the patient.

5. The gas delivery system of claim 4 , wherein the at least one sensor measures the concentration of nitric oxide in the breathing circuit.

6. The gas delivery system of claim 1 , further comprising:

a display configured to present the concentration of nitric oxide measured by the at least one sensor.

7. The gas delivery system of claim 6 , wherein the display is configured to present that there is an alarm condition.

8. A gas delivery system comprising:

a system controller including a memory having stored thereon a calibration schedule for performing a plurality of baseline calibrations and a calibration line correlating expected sensor output values from a nitric oxide sensor to nitric oxide gas concentration;

a breathing circuit configured to deliver nitric oxide to a patient; and

the nitric oxide sensor configured to continuously measure a concentration of nitric oxide in the breathing circuit and communicate with the system controller;

wherein the system controller is configured to deliver nitric oxide to the patient according to an input set dosage;

wherein the system controller is configured to identify according to the calibration schedule in the memory when the plurality of baseline calibrations is intended to be performed, accounting for the input set dosage;

wherein the system controller is further configured to schedule a time for executing the plurality of baseline calibrations of the nitric oxide sensor according to the calibration schedule;

wherein the system controller changes the calibration schedule upon a change in the input set dosage;

wherein the calibration schedule is based on the input set dosage;

wherein the system controller is configured to adjust the measurements of the nitric oxide sensor according to the calibration line;

wherein during the plurality of baseline calibrations the nitric oxide sensor measures an output value indicative of a zero concentration of nitric oxide while only being exposed to a gas having a zero concentration of nitric oxide; and

wherein the system controller is configured to offset the calibration line by the absolute value of the output value indicative of a zero concentration of nitric oxide.

9. The gas delivery system of claim 8 , wherein the system controller is configured to postpone the calibration of the nitric oxide sensor when an alarm is active or has been active within a predetermined timeframe from the time the calibration is to be executed.

10. The gas delivery system of claim 8 , wherein the calibration schedule comprises a set of values representing intended intervals between interruptions of the continuous measuring of the nitric oxide concentration.

11. The gas delivery system of claim 10 , wherein the intended intervals vary with respect to the absolute change in set dose.

12. The gas delivery system of claim 8 , wherein the system controller is configured to adjust the calibration line by offsetting the slope of the previous calibration line according to the output value indicative of a zero concentration of nitric oxide.

13. The gas delivery system of claim 8 , wherein the system controller is configured to utilize the type of the nitric oxide sensor when identifying the calibration schedule.

14. The gas delivery system of claim 13 , wherein the nitric oxide sensor is one of a three terminal electrochemical nitric oxide gas sensor and a four terminal electrochemical nitric oxide gas sensor.

15. The gas delivery system of claim 8 , wherein the gas having a zero concentration of nitric oxide is ambient air.

16. A gas delivery system comprising:

a system controller including a memory having stored thereon a calibration schedule for performing a plurality of baseline calibrations and a calibration line correlating expected sensor output values from at least one four terminal electrochemical nitric oxide gas sensor to nitric oxide gas concentration;

a breathing circuit configured to deliver nitric oxide gas to a patient; and

at least one four terminal electrochemical nitric oxide gas sensor configured to continuously measure a concentration of nitric oxide in the breathing circuit and communicate with the system controller;

wherein the system controller is configured to deliver the nitric oxide gas to the patient according to an input set dosage;

wherein the system controller is configured to identify according to the calibration schedule in the memory when the plurality of baseline calibrations is intended to be performed accounting for the input set dosage, wherein the plurality of the baseline calibration occurs sooner based upon a larger change in set dosage;

wherein the system controller is further configured to schedule a time for executing the plurality of the baseline calibration of the at least one four terminal electrochemical nitric oxide gas sensor according to the calibration schedule;

wherein the system controller changes the calibration schedule upon a change in the set dosage;

wherein the calibration schedule is based on the set dosage;

wherein the system controller is configured to adjust the measurements of the at least one four terminal electrochemical nitric oxide gas sensor according to the calibration line;

wherein during the plurality of baseline calibrations the sensor measures an output value indicative of a zero concentration of nitric oxide while only being exposed to a gas having a zero concentration of nitric oxide; and

wherein the system controller is configured to offset the calibration line by the absolute value of the output value indicative of a zero concentration of nitric oxide.

17. The gas delivery system of claim 16 , wherein the plurality of baseline calibrations further occurs according to an absolute change in the set dosage.

Assignments (23)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED COMPANY
Reel/Frame 075393/0608 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043601, FRAME 0025 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0233 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
CHANGE OF NAME Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 056476/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 056433/0640 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043601/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING DAC
Reel/Frame 039740/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 039741/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 039740/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: INO THERAPEUTICS LLC
To: THERAKOS, INC.
Reel/Frame 039740/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: TOLMIE, CRAIG R.; MILSAP, JEFF; ACKER, JARON M.
To: INO THERAPEUTICS LLC
Reel/Frame 039739/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: MALLINCKRODT PHARMA IP TRADING DAC
To: MALLINCKRODT IP
Reel/Frame 039741/0017 →
Continuity (2)
Continuation 14626409 · Feb 19, 2015
Related Publication 20160243328A1 · Aug 25, 2016
Cited By (1)
US 12,674,788